The drug Rwanda plans to roll out is the long-acting injectable Cabotegravir (CAB-LA), an intramuscular, long-acting form of PrEP. The first two injections are administered four weeks apart, followed ...
According to Future Market Insights (FMI), the global asthma treatment market is poised for substantial growth, projected to hit USD 28.0 billion in 2024 and soar to USD 46.0 billion by 2034, with a ...